Shopping Cart 0
Cart Subtotal
AED 0

Neuroimmunology Drug Development

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 29342

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 58683

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 88025

Details

Neuroimmunology Drug Development

Summary

Neuroimmunology is expected to be an area that will witness strong growth in the future due to factors such as deeper understanding of the underlying disease pathology, advancements in neurogenetics, and potential of these drugs that can contribute to targeted therapy. Pipeline drugs targeting a number of neurology indications are being developed; however, the most common ones are Alzheimer's disease (AD) and Multiple Sclerosis (MS).

This report provides an overview of current clinical and product development trends for neuroimmunology within the 8MM (France, Germany, Italy, Spain, UK, US, Japan, China), including analysis of the most common targets and molecule types that are being evaluated among the current pipeline drugs, focus on product development in indications such as AD and MS, and unmet needs within neuroimmunology. Clinical trials analyze ongoing trials by different phases of development and by sponsor type, as well as trends in combination therapy trials.

Scope

This report combines primary research from a cross-specialty panel of neurology experts with in-house analyst expertise to provide an assessment of the development landscape. Components of the slide deck include primary and secondary research -

- Quotes from 10 key opinion leaders (3 US, 5 EU, 1 Japan, 1 China)

- Summary of neuroimmunology product definitions and classifications

- Overview of common targets and molecule types among current pipeline drugs, with focus on product development in AD and MS

- Trends in ongoing clinical trials in neuroimmunology based on sponsor type, and phase of development

- Call-outs of key information and details

- Insight from GlobalData's specialist neurology analysts.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the neuroimmunology market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the neuroimmunology market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

READ MORE

Table Of Content

Scope

1 Table of Contents

1. Introduction

1.1 Related Reports 4

1.2 Upcoming Related Reports 5

2. Executive Summary 7

2.1 Key Findings 8

2.2 KOL Insights on Neuroimmunology Competitive Landscape 9

3. Neuroimmunology Product Definition and Classification 10

3.1 GlobalData's Definition of Neuroimmunology Products 11

4. Overview of Common Targets in Neuroimmunology 12

4.1 Cytokines 14

4.2 Lymphocytes or Molecules Associated with their Activation or Migration 15

4.3 Other Common Targets in Neuroimmunology 16

5. Assessment of Marketed Neuroimmunology Products 17

5.1 Indications and Molecule Types 19

5.2 Target Types 20

6. Assessment of Pipeline Neuroimmunology Products 21

6.1 Products in Different Phases of Development 23

6.2 Products by Different Molecule Types 25

6.3 Products by Different Targets 27

7. Indication Specific Overview: Multiple Sclerosis 37

7.1 Disease Overview and Epidemiology 39

7.2 Product Development Activity 41

7.3 Profiles of Products in Late - Stage Development 42

8. Indication Specific Overview: Alzheimer's Disease 46

8.1 Disease Overview and Epidemiology 48

8.2 Product Development Activity 50

8.3 Profiles of Products in Late - Stage Development 51

9. Trends in Clinical Trials of Neuroimmunology Drugs 57

9.1 Geographical Locations of Ongoing Clinical Trials 59

9.2 Ongoing Clinical Trials by Different Phases and Sponsor Type 60

9.3 Indications Being Evaluated in Ongoing Clinical Trials 62

9.4 Combination Therapy Trends in Ongoing Clinical Trials 63

9.5 Unmet Needs Within Neuroimmunology 66

10. Appendix 69

10.1 Sources 70

10.2 Primary Research 71

10.3 About the Authors 72

10.4 About GlobalData 74

10.5 Contact Us 75

10.6 Disclaimer 76

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

AB Science SA

Actelion Pharmaceuticals Ltd.

AZTherapies Inc.

Biogen Inc.

Celgene Corp.

Novartis AG

F. Hoffmann-La Roche AG

Genetech Inc.

Grifols SA

TG Therapeutics Inc.

TauRX Therapeutics Ltd

Company Profile

Company Profile Title

Neuroimmunology Drug Development

Summary

Neuroimmunology is expected to be an area that will witness strong growth in the future due to factors such as deeper understanding of the underlying disease pathology, advancements in neurogenetics, and potential of these drugs that can contribute to targeted therapy. Pipeline drugs targeting a number of neurology indications are being developed; however, the most common ones are Alzheimer's disease (AD) and Multiple Sclerosis (MS).

This report provides an overview of current clinical and product development trends for neuroimmunology within the 8MM (France, Germany, Italy, Spain, UK, US, Japan, China), including analysis of the most common targets and molecule types that are being evaluated among the current pipeline drugs, focus on product development in indications such as AD and MS, and unmet needs within neuroimmunology. Clinical trials analyze ongoing trials by different phases of development and by sponsor type, as well as trends in combination therapy trials.

Scope

This report combines primary research from a cross-specialty panel of neurology experts with in-house analyst expertise to provide an assessment of the development landscape. Components of the slide deck include primary and secondary research -

- Quotes from 10 key opinion leaders (3 US, 5 EU, 1 Japan, 1 China)

- Summary of neuroimmunology product definitions and classifications

- Overview of common targets and molecule types among current pipeline drugs, with focus on product development in AD and MS

- Trends in ongoing clinical trials in neuroimmunology based on sponsor type, and phase of development

- Call-outs of key information and details

- Insight from GlobalData's specialist neurology analysts.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the neuroimmunology market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the neuroimmunology market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

READ MORE

Scope

1 Table of Contents

1. Introduction

1.1 Related Reports 4

1.2 Upcoming Related Reports 5

2. Executive Summary 7

2.1 Key Findings 8

2.2 KOL Insights on Neuroimmunology Competitive Landscape 9

3. Neuroimmunology Product Definition and Classification 10

3.1 GlobalData's Definition of Neuroimmunology Products 11

4. Overview of Common Targets in Neuroimmunology 12

4.1 Cytokines 14

4.2 Lymphocytes or Molecules Associated with their Activation or Migration 15

4.3 Other Common Targets in Neuroimmunology 16

5. Assessment of Marketed Neuroimmunology Products 17

5.1 Indications and Molecule Types 19

5.2 Target Types 20

6. Assessment of Pipeline Neuroimmunology Products 21

6.1 Products in Different Phases of Development 23

6.2 Products by Different Molecule Types 25

6.3 Products by Different Targets 27

7. Indication Specific Overview: Multiple Sclerosis 37

7.1 Disease Overview and Epidemiology 39

7.2 Product Development Activity 41

7.3 Profiles of Products in Late - Stage Development 42

8. Indication Specific Overview: Alzheimer's Disease 46

8.1 Disease Overview and Epidemiology 48

8.2 Product Development Activity 50

8.3 Profiles of Products in Late - Stage Development 51

9. Trends in Clinical Trials of Neuroimmunology Drugs 57

9.1 Geographical Locations of Ongoing Clinical Trials 59

9.2 Ongoing Clinical Trials by Different Phases and Sponsor Type 60

9.3 Indications Being Evaluated in Ongoing Clinical Trials 62

9.4 Combination Therapy Trends in Ongoing Clinical Trials 63

9.5 Unmet Needs Within Neuroimmunology 66

10. Appendix 69

10.1 Sources 70

10.2 Primary Research 71

10.3 About the Authors 72

10.4 About GlobalData 74

10.5 Contact Us 75

10.6 Disclaimer 76

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

AB Science SA

Actelion Pharmaceuticals Ltd.

AZTherapies Inc.

Biogen Inc.

Celgene Corp.

Novartis AG

F. Hoffmann-La Roche AG

Genetech Inc.

Grifols SA

TG Therapeutics Inc.

TauRX Therapeutics Ltd